Interaction between Triamterene and Spironolactone
Major
Synergy
| ID | DDInter1859 and DDInter1707 |
| Interaction | The principal risk of potassium-sparing diuretics is hyperkalemia. There may be an additive risk when more than one of these agents are used simultaneously. Death has been reported in patients receiving spironolactone in combination with triamterene-containing diuretics. |
| Management | Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, the concurrent use of more than one potassium-sparing diuretic is considered contraindicated. |
| References | |
| Alternative for Triamterene |
C03D
|
| Alternative for Spironolactone |
C03D
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.